Cite
APA Citation
Camidge, D., Bazhenova, L., Salgia, R., Langer, C., Gold, K., Rosell, R., Shaw, A., Weiss, G., Dorer, D., Rivera, V., Conlan, M., Kerstein, D., & Gettinger, S. (n.d.). 3061 Assessment of Brigatinib (AP26113) CNS Activity in Patients (Pts) With ALK+ NSCLC and intracranial metastases in a Phase 1/2 Study. European journal of cancer, 51, S616–. http://access.bl.uk/ark:/81055/vdc_100030628298.0x000008